Health
How PSA Monitors Prostate Cancer Progression
Health Points
- PSA levels help track prostate cancer after diagnosis and treatment.
- Different markers signal recurrence based on surgery or radiation history.
- Advancing diagnostics and PSA trends guide ongoing care decisions.
Prostate-specific antigen (PSA) testing remains a vital tool in monitoring men with prostate cancer. It helps determine disease progression and guides future treatment steps.
After surgery, PSA should be undetectable, while radiation lowers PSA levels toward a minimum called the nadir.
“Using PSA to monitor cancer progression is one of the most useful tools we have,” Dr. Marc B. Garnick notes.
If PSA rises after prostate removal, it signals possible remaining cancer cells—a situation known as biochemical recurrence.
For men treated with radiation, a rise in PSA of at least 2 ng/mL over the nadir also marks potential recurrence.
Doctors may follow slower PSA increases, but faster doubling times prompt additional attention and intervention.
New tests now detect prostate-specific membrane antigen (PSMA) to spot small cancer spots that might be missed on standard scans.
Regular monitoring, typically every three months, assesses how well therapies are working—often allowing for changes in care if PSA stays low and metastases aren’t seen.
“A significant drop in PSA of 50% or more is considered a positive indicator of treatment response,” Dr. Garnick explains.
Consistent PSA monitoring is crucial not only for current therapies but also for evaluating experimental treatments for advanced prostate cancer.
Stay informed about advances in PSA testing and talk to your healthcare provider about what changes in your results may mean for your care.